MIA Polyclonal Antibody

The product of CHD4 belongs to the SNF2/RAD54 helicase family. It represents the main component of the nucleosome remodeling and deacetylase complex and plays an important role in epigenetic transcriptional repression. Patients with dermatomyositis develop antibodies against this protein. Somatic mutations in this gene are associated with serous endometrial tumors. Alternative splicing results in multiple transcript variants encoding different isoforms.

The MIA Polyclonal Antibody is a highly specific and reliable tool for the detection and quantification of Melanoma Inhibitory Activity (MIA) protein in various biological samples. This antibody has been meticulously developed and rigorously validated to ensure optimal performance and accuracy in research and diagnostic applications.

The MIA Polyclonal Antibody exhibits exceptional sensitivity and specificity, enabling precise and reproducible results. It has been extensively tested in a variety of experimental conditions, including Western blotting, immunohistochemistry, and ELISA, demonstrating consistent and robust performance across multiple platforms.

This antibody is produced using state-of-the-art techniques, ensuring high purity and batch-to-batch consistency. It is derived from a polyclonal source, resulting in a diverse population of antibodies that recognize different epitopes of the MIA protein. This broad recognition profile enhances the versatility and reliability of the antibody, making it suitable for a wide range of experimental designs and applications.

The MIA Polyclonal Antibody is supplied in a convenient and user-friendly format, allowing for easy handling and storage. It is provided as a liquid formulation, eliminating the need for reconstitution and minimizing the risk of sample contamination. The antibody is also available in various sizes to accommodate different experimental requirements.

With its exceptional performance, reliability, and ease of use, the MIA Polyclonal Antibody is an indispensable tool for researchers and clinicians studying the role of MIA protein in various biological processes and diseases, particularly in the context of melanoma. Trust in the MIA Polyclonal Antibody to deliver accurate and reproducible results, enabling advancements in scientific understanding and clinical diagnostics.